ClinicalTrials.gg
CompletedNCT04539548Updated Apr 15, 2024

A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract

A Phase 3 interventional study of Dextenza Ophthalmic Insert and Prednisolone acetate ophthalmic suspension USP 1% in Cataract, sponsored by Ocular Therapeutix, Inc.. Completed at 14 sites in United States. Open to participants aged 0 Years to 5 Years. Per ClinicalTrials.gov, last updated 2024-04-15.

Sponsored by Ocular Therapeutix, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2023, 2 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
0 Years to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 34 studies testing dexamethasone in Cataract — 1 open to participants now, 1 under way, 1 of them phase 3. Dexamethasone · Cataract.

Enrollment
16th of 34
65 · median 50
Started
2020
with 6 others
Phase 3
9 of 34
1 open now
Registered
13th of 34
by date

Among the 34 studies testing dexamethasone in Cataract, this one is the 16th largest by enrollment, is one of 7 that started in 2020, is one of 9 in phase 3, and was the 13th registered.

Cataract

1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.

Browse Cataract studies →

Open to participants now

1 of the 34 studies testing dexamethasone in Cataract is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: 0 Years to 5 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing dexamethasone in Cataract, or all of them as a file.
02

Study summary

To assess the safety of Dextenza compared to an active control, prednisolone acetate suspension, for the treatment of postoperative pain and inflammation following ocular surgery for pediatric cataract.

Read the detailed description

Randomized, parallel-arm, active control, multi-center study assessing the safety of Dextenza for the treatment of ocular pain and inflammation following surgery for pediatric cataract. The subjects will be followed for approximately 2-3 months from screening to the last visit.

03

Conditions studied

  • Cataract

Browse trials for

Keywords

  • Dextenza, dexamethasone ophthalmic insert
04

Who can participate

Ages eligible
0 Years to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is 0-5 years of age (up to the day before the subject turns 6 years of age). In the event that a subject aged 0-5 years enrolls in the study and then undergoes a second cataract surgery in the contralateral eye during the study period, the subject remains eligible for participation for both eyes, regardless if the second surgery occurs when the subject is >5 years of age)
  • Has a cataract and is expected to undergo primary cataract surgery with or without implantation of a posterior chamber intraocular lens

Exclusion criteria

Exclusion Criteria:

  • Any intraocular inflammation in the study eye present during the screening slit lamp examination
  • Has ocular hypertension (defined as IOP of >21 mmHg), or glaucoma or is on medications to treat ocular hypertension or glaucoma or has a history of IOP spikes in either eye including -related IOP increases
  • Evidence of acute external ocular infections (bacterial, viral and/or fungal such as vaccinia, varicella, and other viral diseases of the cornea and conjunctiva), tuberculosis of the eye; corneal dystrophies; active corneal ulcers, intraocular infections, dysthyroid ophthalmopathy, active chalazion, or uncontrolled blepharitis in the study eye
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Dextenza

    1 dosing group - 37 eyes treated with Dextenza

    Drug: Dextenza Ophthalmic Insert

  • Active comparator
    Prednisolone

    1 dosing group - 32 eyes treated with Prednisolone

    Drug: Prednisolone acetate ophthalmic suspension USP 1%

Interventions

  • 0.4mg insert for intracanalicular use

    Also known as: DEXTENZA

  • DrugPrednisolone acetate ophthalmic suspension USP 1%

    1 drop at end of surgery, followed by: 1 drop 4 x QID for one week. 1 drop 3 x QID for one week. 1 drop BID for one week. 1 drop QD for one week

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Number of Ocular Treatment Emergent Adverse Events (TEAEs) and Non-ocular Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to approximately 42 days after surgery

  2. Subject FLACC Pain Assessment

    Behavioral Observation Pain Rating Scale from 0 (no pain) to 10 (most pain).

    Time frame: From screening through day 42

  3. IOP

    IOP measured in units of mmHg.

    Time frame: From screening, then day 2 through 42

07

Study locations

14 sites
  • Ocular Therapeutix
    Aurora, Colorado 80045, United States
  • Ocular Therapeutix
    Fort Collins, Colorado 80525, United States
  • Ocular Therapeutix
    Jacksonville, Florida 32202, United States
  • Ocular Therapeutix
    Indianapolis, Indiana 46202, United States
  • Ocular Therapeutix
    Lexington, Kentucky 40508, United States
  • Ocular Therapeutix
    Boston, Massachusetts 02115, United States
  • Ocular Therapeutix
    Minneapolis, Minnesota 55454, United States
  • Ocular Therapeutix
    Rochester, Minnesota 55905, United States
  • Ocular Therapeutix
    Saint Louis, Missouri 63110, United States
  • Ocular Therapeutix
    Erie, Pennsylvania 16501, United States
  • Ocular Therapeutix
    Charleston, South Carolina 29425, United States
  • Ocular Therapeutix
    Nashville, Tennessee 37232, United States
  • Ocular Therapeutix
    Virginia Beach, Virginia 23452, United States
  • Ocular Therapeutix
    Madison, Wisconsin 53705, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Dec 2023, 39 months.

Of 23 industry-sponsored phase 3 interventional studies under Cataract, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 15. This study's 39 months is above that.

Counting every sponsor, half of 31 studies reached it within 13 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2020
First posted
Sep 7, 2020
StartActual
Sep 4, 2020
Primary completionActual
Dec 21, 2023
CompletionActual
Dec 21, 2023
Last update
Apr 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04539548
Responsible party
Sponsor
First posted
Sep 7, 2020
Start date
Sep 4, 2020
Primary completion
Dec 21, 2023
Completion
Dec 21, 2023
Last update
Apr 15, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion